Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are studying circulating DNA cDNA as a potential biomarker to detect residual disease following chemoradiotherapy in patients with locally advanced head and neck squamous cell carcinoma. This ancillary clinical trial focuses on whether cDNA can identify residual disease three months after treatment by comparing cDNA detection results with clinical and radiological assessments. Participants will undergo blood sampling, where 18 mL of blood is collected at one and three months after completing chemoradiotherapy. These blood samples are used to assess the presence and kinetics of circulating DNA, and researchers will also study mutational profiles and HPV genotypes in relation to the tumor and ctDNA at diagnosis. During the trial, participants provide blood samples at specified times and are monitored for objective response to treatment and survival outcomes. Researchers measure cDNA detection and compare it with clinical responses at one and three months post-treatment. The study is conducted alongside the main Neck-TAR study, and participation involves blood draws and follow-up evaluations up to 27 months after treatment to assess progression-free and overall survival.
Actively Recruiting
Researchers are studying the use of ribociclib, a CDK46 inhibitor, in women with early hormone receptor-positive HR and HER2-negative breast cancer who are at intermediate risk of cancer recurrence. The study aims to see if patients can avoid chemotherapy, which has significant side effects, by using ribociclib along with hormone therapy after surgery. This phase III trial builds on the NATALEE study, which showed that ribociclib added to hormone therapy improved survival free of invasive disease in similar patients. Participants will be randomly assigned to one of two groups one receiving ribociclib plus endocrine hormone therapy, and the other receiving chemotherapy followed by ribociclib and endocrine therapy. Ribociclib treatment lasts for three years, and chemotherapy is given before starting ribociclib and hormone treatment. The trial aims to compare the outcomes of chemotherapy de-escalation versus standard treatment in this patient group. During the study, participants will attend scheduled visits for treatment and monitoring, including laboratory tests, heart monitoring with ECG, and questionnaires about their quality of life. Researchers will track invasive breast cancer-free survival and other outcomes such as overall survival and treatment side effects for up to 12 years. Safety and quality of life assessments will continue during and after treatment to evaluate the long-term effects and benefits of the treatment approaches.
Actively Recruiting
Researchers are studying how to adjust the dose of fluoropyrimidine chemotherapy based on uracilemia levels in patients with DPD deficiency who have gastrointestinal cancers. This phase II multicenter trial aims to find the best dose reduction strategy to reduce side effects while treating digestive cancers. The main question is which dose reduction is needed for patients with this enzyme deficiency. Participants will receive chemotherapy with doses adjusted according to their uracilemia level. Patients with low uracilemia <16 ngmL will get the full dose, while those with higher levels will receive varying dose reductions or random assignments between 25% and 50% reductions depending on their uracilemia range. Treatments include the FOLFOX or CAPOX chemotherapy regimens, given in cycles every 2 to 3 weeks. During the study, participants will visit the clinic every 2 to 3 weeks for checkups and tests to monitor side effects and treatment response. Researchers will measure the occurrence of serious blood and gastrointestinal toxicities after two treatment cycles and track dose adjustments, toxicity, and survival outcomes over several months and years. The study involves close monitoring of health and treatment effects for up to three years, depending on cancer stage.
Actively Recruiting
Researchers are conducting an observational study called the France PCI Registry to monitor and improve care in interventional cardiology, focusing on procedures like coronary angiography and angioplasty. This national observatory started in 2014 in the Centre Val de Loire region and aims to build a reliable database of interventional cardiology activities. The study is led by the Club Rgional des Angioplasticiens de la rgion Centre and seeks to optimize patient care times, especially for those with STEMI a type of heart attack. The study collects data fully integrated with usual coronary activity reporting software across multiple catheterization labs. It tracks interventional cardiology activities over a year and monitors secondary outcomes such as improving care times for STEMI patients within 24 hours. There are no investigational drugs or treatments administered, as this is an observational study gathering information from routine clinical practice. Participants who have undergone coronary angiograms or angioplasty are involved through data collection during their usual care. The study regularly evaluates data quality to maintain an exhaustive and reliable database. Researchers measure the volume and quality of interventional cardiology procedures and how quickly STEMI patients receive care. Participation lasts as long as the data collection period, with ongoing observation but no additional interventions or treatments.
Actively Recruiting
Researchers are investigating the best noninvasive respiratory support method for patients in intensive care units ICUs who develop respiratory failure after planned removal of their breathing tube extubation. This condition affects about 20% of ICU patients, and many require reintubation, which is linked to high mortality rates. The study aims to compare whether alternating non-invasive ventilation NIV with high-flow nasal oxygen reduces death rates compared to high-flow nasal oxygen alone in these patients. The trial is a multicenter, randomized, controlled study where patients with post-extubation respiratory failure are assigned to one of two groups. One group receives continuous high-flow nasal oxygen treatment for 48 hours, while the other group receives NIV alternating with high-flow nasal oxygen during the same period. NIV involves pressure-support breathing with specific settings to help patients breathe, and the study ensures balance in patient groups based on carbon dioxide levels in the blood. Participants will be closely monitored with assessments including timing of death, reintubation events, days without ventilator use, length of ICU and hospital stay, and mortality at different time points up to 90 days. The main outcome measured is death rate 28 days after respiratory failure onset. The study includes clinical evaluations and blood gas tests to guide treatments and decisions. Participation duration includes the initial 48-hour treatment period and follow-up assessments extending to 90 days.
Actively Recruiting
Squamous cell carcinoma of the anus is a rare but increasingly common cancer, often linked to human papillomavirus HPV. For early-stage tumors, combined radiotherapy and chemotherapy with 5FU and mitomycin-C provide good outcomes, but advanced tumors have a poor prognosis with a high relapse rate. Researchers are studying a new approach combining induction chemotherapy with docetaxel, cisplatin, and 5FU mDCF followed by standard chemoradiotherapy to improve treatment results for locally advanced anal cancer T3-4 or N1. This is a randomized phase 3 trial comparing this new strategy to the current standard treatment. The study includes two groups one receives the usual chemoradiotherapy, which involves 33 radiotherapy sessions over 6.5 weeks combined with mitomycin-C and capecitabine chemotherapy taken on radiotherapy days. The other group starts with 4 cycles of mDCF chemotherapy given every two weeks before receiving the same chemoradiotherapy as the control group. Radiotherapy uses intensity-modulated external irradiation with a targeted boost to the tumor and involved lymph nodes. Participants will be followed after treatment with check-ups at 8 weeks, then every 4 months for two years, and every 6 months in the third year. Follow-up includes clinical exams and imaging scans CT and MRI. The main measure of success is disease-related event-free survival two years after treatment. Other outcomes include overall survival, colostomy-free survival, treatment side effects, tumor response, and quality of life. The total study duration for each participant may extend over several years including this follow-up period.
Actively Recruiting
Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.
Actively Recruiting
Researchers are investigating the use of circulating DNA detection to predict residual disease in patients with locally advanced head and neck squamous cell carcinomas HNSCCs treated with potentiated radiotherapy. Locally advanced HNSCCs have high rates of locoregional failure, and current imaging methods like PET-CT have limitations in accurately detecting residual disease due to false positives caused by inflammation. This study aims to assess whether circulating tumor DNA ctDNA, including circulating HPV16 viral DNA cvDNA, can provide more reliable information about treatment response and residual disease. Participants will have blood samples collected twice once before treatment and again three months after radiochemotherapy if imaging shows an incomplete response. The study focuses on patients undergoing potentiated radiotherapy combined with chemotherapy regimens including Docetaxel, Platinum, and 5-Fluorouracil. This single-arm, open-label, multicenter study monitors ctDNA and compares it with PET-CT results to evaluate its value in detecting residual disease and predicting patient outcomes. During the study, participants will undergo PET-CT scans and blood sampling to measure ctDNA levels. Researchers will track the rate of incomplete cervical lymph node response on PET-CT and the presence of circulating DNA three months after treatment. Additional assessments include evaluating concordance between tumor and circulating DNA profiles, reproducibility of imaging interpretations, and long-term monitoring of clinical and pathological features. The study extends up to 66 months to observe outcomes and includes regular clinical follow-up to assess the prognostic value of ctDNA and HPV-related markers.
Actively Recruiting
Researchers are evaluating whether giving amiodarone for 72 hours can reduce deaths and severe heart rhythm problems within 30 days in critically ill adults admitted after an out-of-hospital cardiac arrest with an initial shockable heart rhythm and a confirmed or suspected cardiac cause. This phase 3 trial is randomized and compares patients receiving amiodarone to those receiving no intervention. The study is sponsored by Versailles Hospital. Participants in the amiodarone group receive an initial 300 mg loading dose over 30 minutes, followed by a continuous infusion for 72 hours at 10 mgkg per day, not exceeding 900 mg per 24 hours. The control group does not receive amiodarone. Treatment starts shortly after admission to intensive care and screening. The study measures outcomes for up to 90 days, including heart-related events, mortality, ventilation duration, neurological status, vasopressor use, and hospital stay length. During the study, patients are closely monitored in intensive care with regular assessments of their heart condition and overall health. Researchers track serious ventricular arrhythmias and death rates over 30 days as the main outcome. Secondary outcomes include longer-term cardiac events, neurological outcomes, and side effects related to amiodarone within 5 days. The total follow-up lasts up to 90 days, during which participants responses to treatment and safety are carefully observed.
1-10 of 19
1